The Department of Biotechnology (DBT) and BIRAC, under the BioE3 Policy, have announced a joint call for proposals to support the development and manufacturing of monoclonal antibodies (mAbs) as part of India's high-performance biomanufacturing initiative. The goal is to enhance access to affordable, high-quality biotherapeutics, strengthen the country's position as a global hub for biotechnology, and build capacity to respond to ongoing and future healthcare needs. Proposals are invited in two categories: (i) Discovery & Application (Technology Readiness Level 3–5), which includes research on novel mAbs for new therapeutic targets, antibody engineering, infectious diseases, diagnostics, and overcoming resistance mechanisms; and (ii) Bridging the Gap for Scale-up (TRL 5–8), which focuses on scaling up bio-betters, manufacturing raw materials indigenously, and validating technologies for commercial readiness. The call is open to academic and research institutions, startups, companies, and LLPs with required credentials and a minimum of 51% Indian ownership.
Last date: May 16, 2025
